Halozyme Therapeutics, Inc.
HALOBiotechnologyClosed
102.88-7.4%Up to 1000x leverageTrade HALO
What it reported
Reported 5 days ago, on 2026-11-05.
Forecast against the result
| Forecast | Reported | Surprise | |
|---|---|---|---|
| Revenue | 491.6M | 493.0M+39.2% year on year | +0.3% |
| Earnings per share | 2.30 | 2.39+39.0% year on year | +3.9% |
Year on year compares the same quarter a year earlier (2025-11-03), not the quarter before.
HALO trades at up to 1000x here. At 1000x, a 0.10% move against you wipes out the whole margin. This ignores fees, funding and maintenance margin, all of which bring liquidation forward. Your actual liquidation price is the one shown on the order page.
You can hold through the announcement here
HALO is quoted here 24 hours a day and does not stop when the US market closes. On a US exchange the same news only shows up as a gap at the next open.
Track record
Next report expected 2027-02-16. Reports quarterly.
Beat estimates 7 of the last 8 quarters. The typical gap is +0.09 per share.
Reported results
| Reported | EPS forecast | EPS actual | Surprise | Revenue surprise |
|---|---|---|---|---|
| 2026-11-05 | 2.3 | 2.39 | +3.9% | +0.3% |
| 2026-08-06 | 1.79 | 2.28 | +27.4% | +19.6% |
| 2026-05-11 | 1.55 | 1.6 | +3.2% | +5.0% |
| 2026-02-17 | 2.15 | -0.24 | -111.2% | +3.7% |
| 2025-11-03 | 1.63 | 1.72 | +5.5% | -20.7% |
| 2025-08-05 | 1.23 | 1.54 | +25.2% | -1.5% |
| 2025-05-06 | 0.95 | 1.11 | +16.8% | -5.7% |
| 2025-02-18 | 1.17 | 1.26 | +7.7% | +4.3% |
| 2024-10-31 | 0.98 | 1.27 | +29.6% | -0.9% |
| 2024-08-06 | 0.76 | 0.91 | +19.7% | +10.7% |
| 2024-05-07 | 0.7 | 0.79 | +12.9% | -2.0% |
| 2024-02-20 | 0.83 | 0.82 | -1.2% | -0.5% |
Also reporting this fortnight in Biotechnology
CYTK 
GMAB 
IOVA 
MRNA 
ROIV 
RVMD 3 more in Biotechnology
EPS history for HALO runs from 2002-05-15 to 2026-11-05, 90 reports.